When was Epic Sciences founded?

Epic Sciences was founded in 2008 and raised its 1st funding round 1 year after it was founded.

Where is Epic Sciences located?

Epic Sciences is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does Epic Sciences have?

As of Mar 01, 2026, the latest employee count at Epic Sciences is 50 - 199.

Is Epic Sciences a funded company?

Epic Sciences is a funded company, having raised a total of $204M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 30, 2009.

When was the latest funding round of Epic Sciences?

Epic Sciences' latest funding was a $***** Series G round on Apr 14, 2023, with participation from 5 investors.

Where does Epic Sciences rank among its competitors?

Epic Sciences ranks 56th amongst 526 active competitors, of which 157 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Delfi Diagnostics, which secured $34.3M in Dec, 2025.

Who are the top competitors of Epic Sciences?

Epic Sciences' top competitors include Guardant Health, Natera and Myriad Genetics. Among them, Delfi Diagnostics secured the most recent funding round in December, 2025.

Epic Sciences - 2026 Company Profile, Funding & Competitors

Epic Sciences is a series G company based in San Diego (United States), founded in 2008. It operates as a Provider of non-invasive tests for the detection of circulating tumor cells. Epic Sciences has raised $204M in funding from investors like Arsenal Capital Partners, Venrock and Roche. The company has 526 active competitors, including 157 funded and 116 that have exited. Its top competitors include companies like Guardant Health, Natera and Myriad Genetics.

Company Details

Provider of non-invasive tests for the detection of circulating tumor cells. The proprietary platform uses specialized assays and advanced digital pathology algorithms to identify circulating tumor cells from whole blood. The flagship product is Epic AR-V7 which detects the presence of AR-V7 biomarker in whole blood and associates it with the response rate for treatment with Zytiga and Xtandi. The first proposed application is metastatic castration-resistant prostate cancer.

Website: epicsciences.com
Social
Registered Address: San Diego, California

Key Metrics

Founded Year

2008

Location

San Diego, United States

Stage

Series G

Total Funding

$204M in 7 rounds

Latest Funding Round

Series G, Apr 14, 2023, $*****

Investors

Arsenal Capital Partners & 22 more

Ranked

56^th among 526 active competitors

Employee Count

50 - 199 as on Mar 01, 2026

Similar Companies

Guardant Health & 598 more

View Epic Sciences' full profile

Epic Sciences is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Epic Sciences, Inc. CIN: 611577455 , United States, Active	Sep 02, 2008	-	60 (As on Dec 31, 2024)	-

Epic Sciences has raised a total funding of $204M over 7 rounds. Its first funding round was on Jun 30, 2009. Its latest funding round was a Series G round on Apr 14, 2023 for $*****. 5 investors participated in its latest round. Epic Sciences has 23 institutional investors.

Here is the list of recent funding rounds of Epic Sciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 14, 2023	2850007	Series G	5459800	8584458	8058024	6537836
Jun 01, 2022	6396101	Series F	8157509	3406032	7219165	Blue Ox Healthcare Partners & 2 more
Sep 12, 2018	6800685	Series E	7701669	5381380	Blue Ox Healthcare Partners	Deerfield & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Epic Sciences's funding rounds and investors

Epic Sciences' employee count trend

Epic Sciences has 50 - 199 employees as of Mar 26. Here is Epic Sciences's employee count trend over the years:

Uncover Epic Sciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Epic Sciences include Guardant Health, Natera and Myriad Genetics. Here is the list of Top 10 competitors of Epic Sciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	Khosla Ventures, Orbimed & 25 others	79/100
2nd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Foresite Capital & 17 others	77/100
3rd	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	72/100
4th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Deerfield, Casdin Capital & 11 others	71/100
5th	Exact Sciences 1995, Madison (United States), Acquired	Provider of non-invasive molecular diagnostic testing solutions for cancer	-	Petrillo Capital, Back Bay Group & 8 others	71/100
6th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	70/100
7th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Beyond Ventures, Ping An Ventures & 21 others	70/100
8th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
9th	Delfi Diagnostics 2019, Baltimore (United States), Series B	Provider of DNA sequencing for cancer detection	$332M	Merck Global Health Innovation Fund, DFJ Growth ... & 19 others	68/100
10th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
56th	Epic Sciences 2008, San Diego (United States), Series G	Provider of non-invasive tests for the detection of circulating tumor cells	$204M	Deerfield, Domain Associates & 21 others	43/100